CHRISTOPHER W. CAIN - 10 Mar 2025 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Director
Signature: /s/ Jennifer Tousignant, Attorney-in-fact
Issuer symbol: VRDN
Transactions as of: 10 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 12 Mar 2025, 16:19:43 UTC
Previous filing: 13 Jun 2024
Next filing: 01 May 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRDN	Stock Option (Right to Buy)	Award	$0	+42,000		$0.000000	42,000	10 Mar 2025	Common Stock	42,000	$15.58	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests and becomes exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
F2	Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The option vests and becomes exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.